Unger, Lukas W.
Forstner, Bernadette
Muckenhuber, Moritz
Scheuba, Katharina
Eigenbauer, Ernst
Scheiner, Bernhard
Pfisterer, Nikolaus
Paternostro, Rafael
Trauner, Michael
Mandorfer, Mattias
Reiberger, Thomas http://orcid.org/0000-0002-4590-3583
Article History
Received: 27 August 2019
Accepted: 5 December 2019
First Online: 24 December 2019
Compliance with Ethical Standards
:
: Lukas W. Unger, Bernadette Forstner, Moritz Muckenhuber, Katharina Scheuba, Ernst Eigenbauer, Bernhard Scheiner, Nikolaus Pfisterer, and Rafael Paternostro have no conflicts of interest to declare. Michael Trauner has served a speaker for BMS, Falk Foundation, Gilead and MSD; advisory boards for Albireo, Falk Pharma GmbH, Genfit, Gilead, Intercept, MSD, Novartis, Phenex and Regulus. He further received travel grants from Abbvie, Falk, Gilead and Intercept and unrestricted research grants from Albireo, Cymabay, Falk, Gilead, Intercept, MSD and Takeda. He is also co-inventor of patents on the medical use of norUDCA filed by the Medical University of Graz. Mattias Mandorfer has served as a speaker and/or consultant and/or advisory board member for AbbVie, Bristol-Myers Squibb, Gilead, and W. L. Gore & Associates. Thomas Reiberger has served as a speaker and/or consultant and/or advisory board member for AbbVie, Bayer, Boehringer Ingelheim, Gilead, W. L. Gore & Associates, and MSD and has received research funding from AbbVie, Boehringer Ingelheim, Gilead, MSD, Phenex Pharmaceuticals, and Philips.